ImmuCell Corporation Cash Flow Conversion Efficiency
ImmuCell Corporation cash flow conversion efficiency. Based on the latest financial reports, ImmuCell Corporation (ICCC) has a cash flow conversion efficiency ratio of 0.096x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.02 Million) by net assets ($31.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ImmuCell Corporation (1989–2025)
Cash flow conversion efficiency of ImmuCell Corporation from 1989 to 2025. This chart illustrates how ImmuCell Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ImmuCell Corporation (ICCC) share price today for real-time trading data and today's change.
ImmuCell Corporation Cash Flow Conversion Ratio Explained
ImmuCell Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ImmuCell Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmuCell Corporation ranked by their cash flow conversion efficiency. Also see ICCC market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
0.036x |
|
GEA Grenobl. Elect.
PA:GEA
|
0.134x |
|
Intelligent Digital Integrated Security Co. Ltd
KQ:143160
|
0.041x |
|
RiTdisplay Corp
TW:8104
|
-0.001x |
|
Laramide Resources Ltd
AU:LAM
|
-0.006x |
|
Novem Group S.A.
XETRA:NVM
|
0.229x |
|
Cellectis
PA:ALCLS
|
-0.348x |
|
Right Way Industrial Co Ltd
TW:1506
|
0.008x |
Annual Cash Flow Conversion Efficiency for ImmuCell Corporation (1989–2025)
The table below shows the annual cash flow conversion efficiency of ImmuCell Corporation from 1989 to 2025. Review cash generation quality of ImmuCell Corporation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.06 Million | $2.48 Million | 0.091x | +603.45% |
| 2024-12-31 | $27.52 Million | $357.90K | 0.013x | +106.95% |
| 2023-12-31 | $24.99 Million | $-4.67 Million | -0.187x | -268.02% |
| 2022-12-31 | $30.38 Million | $-1.54 Million | -0.051x | -273.50% |
| 2021-12-31 | $32.58 Million | $954.17K | 0.029x | -37.07% |
| 2020-12-31 | $28.27 Million | $1.32 Million | 0.047x | +477.85% |
| 2019-12-31 | $28.99 Million | $233.51K | 0.008x | +146.90% |
| 2018-12-31 | $21.74 Million | $-373.40K | -0.017x | -134.46% |
| 2017-12-31 | $23.59 Million | $1.18 Million | 0.050x | +403.43% |
| 2016-12-31 | $19.72 Million | $-323.90K | -0.016x | -106.01% |
| 2015-12-31 | $10.61 Million | $2.90 Million | 0.273x | +736.69% |
| 2014-12-31 | $9.26 Million | $302.36K | 0.033x | -72.07% |
| 2013-12-31 | $9.40 Million | $1.10 Million | 0.117x | +212.19% |
| 2012-12-31 | $9.19 Million | $344.39K | 0.037x | +1005.44% |
| 2011-12-31 | $9.02 Million | $-37.31K | -0.004x | +95.25% |
| 2010-12-31 | $9.28 Million | $-808.61K | -0.087x | -664.32% |
| 2009-12-31 | $9.62 Million | $-109.67K | -0.011x | -306.85% |
| 2008-12-31 | $9.64 Million | $53.14K | 0.006x | -84.15% |
| 2007-12-31 | $10.06 Million | $349.56K | 0.035x | -76.12% |
| 2006-12-31 | $9.33 Million | $1.36 Million | 0.146x | +62.84% |
| 2005-12-31 | $8.56 Million | $764.78K | 0.089x | -49.14% |
| 2004-12-31 | $7.73 Million | $1.36 Million | 0.176x | -7.76% |
| 2003-12-31 | $7.37 Million | $1.40 Million | 0.190x | -30.22% |
| 2002-12-31 | $6.95 Million | $1.90 Million | 0.273x | +82.16% |
| 2001-12-31 | $6.05 Million | $906.00K | 0.150x | +918.37% |
| 2000-12-31 | $5.54 Million | $81.50K | 0.015x | -93.90% |
| 1999-12-31 | $2.82 Million | $679.70K | 0.241x | -11.48% |
| 1998-12-31 | $2.20 Million | $600.00K | 0.273x | +527.27% |
| 1997-12-31 | $2.30 Million | $100.00K | 0.043x | +182.61% |
| 1996-12-31 | $1.90 Million | $-100.00K | -0.053x | -133.33% |
| 1995-12-31 | $1.90 Million | $300.00K | 0.158x | +400.00% |
| 1994-12-31 | $1.90 Million | $-100.00K | -0.053x | -221.05% |
| 1993-12-31 | $2.30 Million | $100.00K | 0.043x | +126.09% |
| 1992-12-31 | $1.80 Million | $-300.00K | -0.167x | +79.17% |
| 1991-12-31 | $1.50 Million | $-1.20 Million | -0.800x | -348.00% |
| 1990-12-31 | $2.80 Million | $-500.00K | -0.179x | -1.19% |
| 1989-12-31 | $3.40 Million | $-600.00K | -0.176x | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more